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SUMMARY 6 
Background 7 
Few studies have reported the systematic use of exclusive enteral nutrition in the perioperative 8 
setting. 9 
Aims 10 
We sought to test the hypothesis that exclusive enteral nutrition provides a safe and effective bridge 11 
to surgery and reduces post-operative complications in adult patients with Crohn’s disease requiring 12 
urgent surgery for stricturing or penetrating complications. 13 
Methods 14 
Patients treated with exclusive enteral nutrition prior to surgery were each matched with two 15 
control patients for disease behaviour, type of surgery, age at diagnosis and disease duration. Data 16 
on disease phenotype, nutritional status, operative course, and post-operative complications were 17 
obtained. 18 
Results 19 
Twenty-five percent [13/51] patients treated with exclusive enteral nutrition avoided surgery. 20 
Exclusive enteral nutrition had no effect on pre-operative weight, but it significantly reduced serum 21 
CRP (median at baseline 36 [interquartile range (IQR) 13-91] vs. pre-operation 8 [4-31] mg/L, 22 
p=0.02). The median [IQR] length of surgery was shorter in patients pre-optimised with exclusive 23 
enteral nutrition than controls (3.0 [2.5-3.5] vs. 3.5 [3.0-4.0] hours respectively, p<0.001). 24 
Multivariable logistic regression analysis confirmed that going straight-to-surgery compared 25 
exclusive enteral nutrition pre-optimisation was associated with a nine-fold increase in the incidence 26 
of post-operative abscess and/or anastomotic leak (OR 9.1 95 %CI [1.2-71.2], p=0.04). 27 
Conclusions 28 
Exclusive enteral nutrition frequently down-stages the need for surgery in patients presenting with 29 
stricturing or penetrating complications of Crohn’s disease and is associated with a reduction in 30 
systemic inflammation, operative times and the incidence of post-operative abscess or anastomotic 31 
leak. Further trials are needed to elucidate how exclusive enteral nutrition may improve operative 32 
outcomes. 33 
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Introduction 34 
Despite improvements in medical care, about 70% patients diagnosed with Crohn’s disease develop 35 
stricturing or penetrating complications necessitating surgery within the first 20 years of diagnosis 36 
1,2. Surgeries are frequently undertaken when patients have exhausted medical options, arguably 37 
when they are at the highest risk of post-operative complications because of the burden of intra-38 
abdominal sepsis, immunosuppression and malnutrition 3. In support of close attention to pre-39 
surgical optimization, in particular the timing of surgery, mortality rates are higher in IBD patients 40 
undergoing emergency rather than planned surgery 4.  41 
Exclusive enteral nutrition involves the use of a liquid nutrition formula to meet all of an individual’s 42 
dietary requirements. For the management of Crohn’s disease, exclusive enteral nutrition is typically 43 
provided for 4-6 weeks before food is re-introduced 5. When tolerated, exclusive enteral nutrition is 44 
as effective as corticosteroids for induction therapy in adult patients with Crohn’s disease 6–13 and in 45 
children is considered the treatment of choice for induction of remission of Crohn’s disease because 46 
of the detrimental effects of corticosteroids, in particular on growth 5,14. However, the higher cost 47 
compared to corticosteroids, and the perception that exclusive enteral nutrition  is poorly tolerated, 48 
limit its use in adults5. 49 
Despite early data reporting that exclusive enteral nutrition improves nutritional status and 50 
inflammation in patients with complicated Crohn’s disease too debilitated to undergo surgery, there 51 
is a paucity of data reporting its systematic use in the perioperative setting 12,15–17. Whether exclusive 52 
enteral nutrition reduces inflammation and down-stages the need for urgent surgery is unknown. 53 
We sought to test the hypothesis that exclusive enteral nutrition reduces post-operative 54 
complications in patients with Crohn’s disease requiring surgery for stricturing or penetrating 55 
complications. 56 
Methods 57 
Study design and clinical setting 58 
We conducted a retrospective case-control study to evaluate the incidence of post-operative 59 
complications in patients with stricturing or penetrating Crohn’s disease who received pre-60 
optimisation with exclusive enteral nutrition and subsequently underwent surgery, compared with 61 
patients who were not pre-optimised and went straight-to-surgery. Patients were matched for 62 
disease behaviour, type of surgery, age at diagnosis, and disease duration. 63 
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The Royal Devon & Exeter (RD&E) NHS Trust is a tertiary referral centre in the South West of England 64 
that serves approximately 3,500 paediatric, adolescent and adult patients with IBD. All of the 65 
colorectal surgeons operating in the Trust undertake urgent surgery on IBD patients. 66 
Screening 67 
Patients who were treated with exclusive enteral nutrition with a documented plan for future 68 
surgery for stricturing or penetrating complications of Crohn’s disease were identified from our 69 
specialist dietician’s database. Index cases were those patients who had received exclusive enteral 70 
nutrition and specialist dietician support, with or without concurrent antibiotic therapy, who had 71 
completed at least 2 weeks of exclusive enteral nutrition treatment prior to surgery. Patients who 72 
received exclusive enteral nutrition and whose symptoms resolved, such that they no longer 73 
required surgery, were excluded. 74 
Matching 75 
Diagnostic coding data were used to identify IBD patients who had undergone surgery between 2008 76 
and 2015. In order to control for the type of complication and complexity of surgery, each index case 77 
was matched to two control patients according to disease behaviour and surgical procedure. In view 78 
of the increased severity and extent of Crohn’s disease diagnosed in childhood 18,19 and that the 79 
accumulation of complications is associated with disease duration 1,2, we then matched for age at 80 
diagnosis (to within 3 years) and disease duration (to within 5 years). Where more than one 81 
potential match on the grounds of age at diagnosis was available, the two individuals with the 82 
closest disease duration were included. 83 
Exclusive enteral nutrition regimen 84 
All patients in the exclusive enteral nutrition group were assessed by a specialist dietician and a 85 
nutritional assessment undertaken. Energy requirements were calculated using the Henry equation 86 
adjusted for activity and a stress factor 20. All patients were treated with oral Modulen IBDTM (Nestlé, 87 
Vevey, Switzerland): volumes were determined by energy requirements and an individual’s 88 
tolerance of a 1 kcal/mL feed. Patients who were unable to tolerate this volume of feed were 89 
provided with a lower volume, more concentrated, regimen. Written information was provided after 90 
the first face-to-face consultation and patients were provided with outpatient or telephone support 91 
once-weekly. Food re-introduction diets were instituted after 6 weeks of exclusive enteral nutrition 92 
and dose adjustments to match calorie requirements were made to the volume of Modulen IBDTM 93 
prescribed. Where applicable (n=6), corticosteroid doses were rapidly weaned when patients were 94 
commenced on exclusive enteral nutrition. 95 
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Data acquisition 96 
Data were recorded from the Trust’s electronic patient record, our IBD database and the case-notes. 97 
Demographic data, smoking status and Charlson co-morbidity index 21 were recorded. The income 98 
measure from English Indices of Deprivation 2015 was determined from the patients’ postcodes 99 
using the tool provided by OpenDataCommunities.org 22. Disease duration, age at diagnosis, IBD 100 
phenotype according to the Montreal Classification 23, pre-operative medical therapy, previous 101 
Crohn’s disease-related surgeries, weight and body mass index, as well as, laboratory and radiology 102 
results at baseline (defined as the day of commencement of exclusive enteral nutrition for index 103 
cases, and the day of surgery in the controls) were recorded. 104 
Duration of exclusive enteral nutrition treatment, post-exclusive enteral nutrition (pre-operative) 105 
weight and body mass index as well as laboratory tests were recorded for index cases. The principal 106 
indication for surgery, surgery type and operative course; including operative time, formation of a 107 
stoma or primary anastomosis, time to first bowel movement and eating, overall length of stay and 108 
incidence and type of surgical complications, as well as, readmission and recurrence rates at 1 year 109 
were collected. 110 
Statistical methods 111 
All analyses were two tailed and p-values <0.05 were considered significant. Univariable analysis of 112 
baseline demographic data comparing patients pre-optimised with exclusive enteral nutrition and 113 
controls was carried out using chi-squared analyses for categorical data, Student’s t-test for 114 
continuous normally distributed variables and Mann-Whitney U tests for nonparametric data. Paired 115 
t-tests and Wilcoxon signed rank tests were used to compare pre- and post-exclusive enteral 116 
nutrition laboratory indices. Univariable analyses using chi-squared analyses and Student’s t-test 117 
tests were used to identify factors associated with post-operative abscesses and/or anastomotic 118 
leak. Checks were made for co-linearity and then these factors were entered into a stepwise forward 119 
multivariable logistic regression model along with the following clinical factors that influence post-120 
operative complications: previous surgery, surgery type and operating surgeon. 121 
Ethical consideration 122 
This project was conducted as a service evaluation and so did not require formal ethical approval in 123 
accordance with the guidelines of the UK Health Research Authority 24. 124 
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Results 125 
Screening & matching 126 
Fifty-one patients who were treated with exclusive enteral nutrition prior to surgery for stricturing 127 
or penetrating complications of Crohn’s disease were identified from our specialist dietician’s 128 
database. Clinical status improved in 25% [13/51] patients such that they no longer required surgery 129 
(Figure 1). 9% [14/150] of potential control patients were excluded on the grounds of surgery type 130 
and disease behaviour and a further 40% [60/150] on the grounds of age at diagnosis and disease 131 
duration (Figure 1). 132 
As a consequence of our matching, there was no difference in the age at diagnosis (median 31.5 133 
[interquartile range (IQR) 25.1-38.5] vs. 30.6 [24.0-43.3] years), disease duration (1.1 [0.3-9.9] vs. 4.6 134 
[0.8-8.8] years), disease location, disease behaviour (Table 1) or type of surgery (Table 2) between 135 
the exclusive enteral nutrition group and control group. 136 
Demographic and socio-economic data 137 
There were no differences in age, gender, ethnicity, income scores, smoking status or co-morbidities 138 
between index cases and controls (Table 1). 139 
At the initiation of exclusive enteral nutrition, no differences were seen in the proportions of 140 
patients treated with 5-aminosalicylates (5-ASAs), immunomodulators (thiopurines or methotrexate) 141 
or biologic agents (infliximab and adalimumab) (Table 1). A small proportion of patients in both 142 
groups were treated with corticosteroids at baseline (Table 1). Patients treated with exclusive 143 
enteral nutrition were more frequently treated with antibiotics than matched controls (29% vs. 11% 144 
respectively, p=0.03). There were no differences in the proportions of cases and controls with 145 
radiological evidence of abscess or collection at baseline or in the proportions that had previous 146 
surgery (Table 1). 147 
Body mass index was lower at baseline in the exclusive enteral nutrition group compared with 148 
controls (p=0.046, Table 2). No differences were seen in baseline full blood counts (FBC) or serum 149 
albumin levels. C-reactive protein (CRP) levels, however, were significantly higher at baseline in 150 
cases than controls (median 36 [IQR 13-91] vs. 7 [3-18] mg/L, p<0.0001). Baseline CRP levels were 151 
higher in patients co-prescribed antibiotics (p<0.001) but there was no difference in CRP levels in 152 
this sub-group immediately before surgery (Figure 2).  153 
Exclusive enteral nutrition treatment 154 
The mean [standard error of the mean (SEM)] duration of exclusive enteral nutrition therapy was 6.3 155 
[0.4] weeks. Overall, 6% [3/51] patients were unable to tolerate at least 4 weeks of exclusive enteral 156 
nutrition. These patients then received courses of prednisolone and were bridged to thiopurine 157 
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therapy. Weight did not increase following exclusive enteral nutrition treatment (median 73 [IQR 158 
60.5-81.6] vs. 73.5 [60.5-81.4] kg, p=0.92). There were no differences in weight or BMI immediately 159 
before surgery between cases and controls (Table 2). 160 
No differences were seen in full blood counts (FBC) or serum albumin levels after exclusive enteral 161 
nutrition pre-optimisation; however, CRP levels in the exclusive enteral nutrition cases were 162 
significantly lower before surgery than at baseline (pre-operation median 8 mg/L [IQR 4-31] vs. 163 
baseline 36 [13-91] mg/L vs., p=0.004, Figure 2).  164 
Exclusive enteral nutrition and antibiotic treatment, but not corticosteroid exposure, were 165 
independently associated with significant reductions in serum CRP levels (Supplementary Table 1). 166 
Given that more patients who were treated with exclusive enteral nutrition were co-prescribed 167 
antibiotics, we repeated the model including antibiotics and exclusive enteral nutrition as interacting 168 
variables; herein, treatment with exclusive enteral nutrition, but not antibiotics alone, was 169 
associated with a reduction in CRP (Supplementary Table 2).  170 
Operative outcomes 171 
No differences were seen in the principal indication for surgery, surgical approach or the proportion 172 
of patients that required a stoma (Table 2). 173 
The median [IQR] length of surgery was shorter in patients pre-optimised with exclusive enteral 174 
nutrition compared to the control group (3 [2.5-3] vs. 3.5 [3.5-4] hours respectively, p<0.001, Figure 175 
2). Furthermore, the length of time to resume oral intake was also less in the exclusive enteral 176 
nutrition cases compared with control patients (2 [1-3] vs. 3 [3-4] days, p<0.001). No differences 177 
were seen in the time to first bowel movement or overall length of stay between cases and controls 178 
(Table 2). 179 
Overall, index patients pre-optimised with exclusive enteral nutrition patients had significantly fewer 180 
surgical complications than control patients who went straight-to-surgery (3/38 [8%] vs. 52/78 [32%] 181 
respectively, p< 0.001, Figure 3) including the rate of formation of an abscess, collections and/or 182 
anastomotic leak (1/38 [3%] in exclusive enteral nutrition group vs. 15/78 [20%] in controls, 183 
p=0.019). No statistically significant differences were seen in readmission or recurrence rates 1 year 184 
after surgery (Table 2). 185 
Factors associated with post-operative abscess/collection or anastomotic leak 186 
As described above, patients directed straight-to-surgery were more likely to suffer an anastomotic 187 
leak, abscess or collection. In univariable analysis increasing length of operation (odds ratio (OR), 188 
95% confidence interval) was also found to be associated with an increased incidence of an 189 
anastomotic leak, abscess or collection (OR 3.3, 95%CI [1.1-11.2], p=0.043) Stepwise multivariable 190 
logistic regression analysis incorporating  previous surgeries, type of surgery and operating surgeon, 191 
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however, demonstrated that going straight-to-surgery was the only independent variable associated 192 
with the incidence of a post-operative abscess/collection or anastomotic leak (OR 9.1 95% CI 1.7-193 
167.9], p=0.036). 194 
Patients whose surgery was complicated by a post-operative abscess/collection or anastomotic leak 195 
had significantly longer length of stays and higher readmission rates than patients who had 196 
uncomplicated surgery (median [IQR] 8 [6-11] days vs. 6 [5-7] days, p=0.011). 197 
Discussion 198 
Several studies have reported the use of exclusive enteral nutrition for induction of remission in 199 
adults and children with active Crohn’s disease; few, however, have been designed to evaluate the 200 
efficacy of exclusive enteral nutrition as a bridge to safer interval surgery and fewer operative 201 
complications. In addition to a more favourable adverse effect profile than corticosteroids and 202 
improved quality of life scores 25, exclusive enteral nutrition has been associated with higher rates of 203 
mucosal healing 26; reductions in serum anti-TNFα levels 27;  increased insulin like growth factor-1 204 
levels 28, improvements in nutritional status 29 and extensive modulation of the intestinal microbiota 205 
30 that could conceivably improve post-operative outcomes. 206 
We sought to test the hypothesis that exclusive enteral nutrition reduces post-operative 207 
complications in patients with stricturing or penetrating complications of Crohn’s disease 208 
necessitating urgent surgery. 209 
Key results and interpretation 210 
In this study, 25% of the patients we treated with exclusive enteral nutrition because of stricturing or 211 
penetrating complications of Crohn’s disease avoided surgery and were bridged to alternative 212 
immunosuppressant therapy. This is similar to rates reported from the early observational studies  of 213 
exclusive enteral nutrition 12,15–17. Despite the widely held belief that exclusive enteral nutrition is 214 
poorly tolerated in adults, 94% of our cohort were able to tolerate more than 4 weeks of exclusive 215 
enteral nutrition treatment, a rate similar to that reported in previous randomised controlled trials 216 
6,8–10,12,31.  217 
Unlike data from clinical trials of EEN in adults with Crohn’s disease 6–13, EEN in our cohort had no 218 
effect on pre-operative weight; possibly because of the relatively short duration of treatment. In 219 
previous reports, significant changes in weight were only reported after 3 months of treatment 5,12.  220 
In common with recent non-matched retrospective studies that reported surgical outcomes in 221 
Crohn’s disease 32,33, and accepting that patients treated herein were more inflamed at baseline and 222 
more frequently co-prescribed antibiotics, exclusive enteral nutrition significantly reduced CRP prior 223 
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to surgery. When exclusive enteral nutrition and antibiotics were co-prescribed we found that their 224 
effects on CRP levels were synergistic. Going straight-to-surgery compared with exclusive enteral 225 
nutrition pre-optimisation was associated with a 9-fold increased risk of a post-operative abscess, 226 
collection or anastomotic leak. We also demonstrated that exclusive enteral nutrition was associated 227 
with shorter operation times. It is conceivable that exclusive enteral nutrition makes surgery 228 
technically easier by reducing the inflammatory burden, and that this leads to a reduction in 229 
complications. 230 
Exclusive enteral nutrition pre-treatment and operation time were the only factors associated with 231 
post-operative abscess, collection or anastomotic leak, with the use of EEN the only independent 232 
variable remaining on multivariable analysis. In contrast to previous studies, we did not demonstrate 233 
associations with smoking status 34, corticosteroids 35 or anti-TNF exposure 36 and the occurrence of  234 
post-operative abscess, collection or anastomotic leak. 235 
Strengths and limitations 236 
Our matched study has several strengths. By comparing our exclusive enteral nutrition cohort with 237 
controls matched for disease behaviour, surgery type, age at diagnosis and duration of diagnosis, we 238 
attempted to avoid selection bias and confounding by differences in disease severity. However, this 239 
will have led to selection of patients with more severe phenotypes with, arguably, an increased risk 240 
of complications than previously reported case series 32,33. Furthermore, given this is a single centre 241 
cohort from a tertiary IBD centre, the patients were each accurately phenotyped, allowing us to look 242 
for differences between demographic characteristics, disease phenotype, and treatment regimens. 243 
Moreover, there was no difference in the proportions of patients with intra-abdominal 244 
sepsis/collection at baseline thus minimising the potential for confounding by severity.  245 
  246 
Conversely, this work has a number of limitations. Because of our retrospective data collection, in 247 
particular for the Montreal classification and surgical disease course, our results are potentially 248 
subject to interpretation bias, and bias because of missing data. Our results might be confounded by 249 
incomplete matching of disease severity. However, despite higher baseline levels of inflammation, 250 
the complication rate was lower in the EEN-treated group. We acknowledge too, that the sample 251 
size is relatively small and that we used a composite primary outcome measure, and that 252 
consequently our conclusions may be subject to a type II error.  253 
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Conclusion  254 
Exclusive enteral nutrition frequently downstages the need for urgent surgery, in patients presenting 255 
with stricturing or penetrating complications of Crohn’s disease. Compared with patients who went 256 
straight-to-surgery matched for surgical type and disease behaviour, age at diagnosis and disease 257 
duration, patients pre-treated with EEN had fewer post-operative complications. This suggests that 258 
exclusive enteral nutrition may be used as a bridge to semi-elective, and arguably therefore, safer 259 
surgery in patients with complicated Crohn’s disease. A randomised-controlled trial is needed to 260 
elucidate how exclusive enteral nutrition may improve operative outcomes and to confirm that 261 
exclusive enteral nutrition provides a safe and effective bridge to surgery.  262 
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Figures 413 
Figure 1: STROBE 37 diagram outlining the screening, matching and inclusion of cases and controls. 414 
Each index case that was treated EEN was matched on surgical procedure, disease behaviour, age at 415 
diagnosis (to within 3 years) and then disease duration (to within 5 years) to two patients that went 416 
straight-to-surgery. Where more than one potential match on the grounds of age at diagnosis was 417 
available, the individual with the closest disease duration was included. 418 
 419 
  420 
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Figure 2: Fold change in CRP in patients treated with or without exclusive enteral nutrition with or 421 
without antibiotics.   422 
 423 
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 442 
Characteristic EEN  
pre-surgery 
(38) 
Matched-
controls 
(76) 
p - value 
Age Age (yrs)      36.3 [30.1-46.6] 39.9 [28-49.5] 0.77 
Sex  Male  21 [55%] 36 [47%] 0.55 
Ethnicity White 38 [100%] 78 [100%] 1.0 
Socio-economic 
status 
Index of Multiple 
Deprivation Score  
0.11 [0.009] 0.11 [0.006] 0.59 
Smoking Current 
Ex 
Never 
13 [34%] 
5 [13%] 
        20 [53%] 
25 [33%] 
9 [12%] 
42 [55%] 
0.28 
Comorbidity Charlson score 0 (0-3) 0 (0-6) 0.31 
Disease 
Duration † 
Disease duration (yrs)  1.1 [0.3-9.9] 4.6 [0.8-8.8] 0.16 
Age at diagnosis (yrs)  31.5 [25.1-38.5] 30.6 [24-43.3] 0. 84 
Montreal 
Classification † 
A1: Age <17 
A2: 17-40 
A3: >40 
3 [8%] 
28 [74%] 
7 [18%] 
3 [4%] 
47 [62%] 
26 [34%] 
0.17 
L1: Ileal 
L2: Colonic 
L3: Ileocolonic  
19 [50%] 
1 [3%] 
18 [47%] 
46 [61%] 
- 
30 [40%] 
0.22 
+ L4: Upper GI  7 [18%] 12 [16%] 0.79 
B1: Inflammatory 
B2: Stricturing 
B3: Penetrating 
- 
18 [47%] 
20 [53%] 
- 
36 [47%] 
40 [53%] 
1.00 
 
+ p: Perianal 3 [8%] 5 [7%] 1.00 
Medications 5 ASA  0 [0%] 5 [7%] 0.17 
Corticosteroids 6 [16%] 8 [11%] 0.43 
Thiopurine 10 [26%] 29 [38%] 0.20 
Methotrexate 0 [0%] 2 [3%] 0.55 
Anti-TNF 3 [8%] 9 [12%] 0.51 
Antibiotics 11 [29%] 9 [11%] 0.03 
Prior surgeries‡ None 26 [68%] 50 [66%] 0.94 
Small bowel resection 4 [11%] 7 [9%] 
Ileocaecal resection 7 [18%] 10 [13%] 
Right hemicolectomy 1 [3%] 9 [12%] 
Radiology  Collection/abscess 8[21%] 17[22%] 1.0 
Laboratory 
indices  
Haemoglobin (g/L) mean 
[SEM] 
127 [2.6] 129 [1.5] 0.62 
MCV (fL) mean [SEM] 85.5 [1.0] 87.2 [0.9] 0.23 
White cell count (x10
9
/L) 
mean [SEM] 
9.3 [0.5] 8.1[0.4] 0.07 
Platelet count (x10
9
/L) mean 
[SEM] 
331 [16.7] 308 [11.3] 0.25 
Albumin (g/L) mean [SEM] 41.8 [0.8] 42.6 [0.5] 0.35 
C-reactive protein (mg/L) 
median [IQR] 
36 [13-91] 7 [3-18] <0.0001 
 443 
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Table 1: Baseline demographic, disease phenotype, concurrent medications, previous surgeries 444 
and laboratory indices in cases and controls. Median and interquartile range (IQR) are presented 445 
unless otherwise stated. SEM denotes standard error of the mean. Differences between parametric 446 
continuous variables and in non-parametric and/or discrete variables were sought using Student’s t-447 
test and the Mann-Whitney U test respectively. Differences between categorical variables were 448 
sought using chi-squared analyses, where n<6 Fisher’s exact test was used. † matching criteria: only 449 
the age at diagnosis and disease behaviour components of the Montreal classification were 450 
matched. ‡ denotes chi-squared analysis between surgery and no surgery.  451 
  452 
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Characteristic EEN  
pre-surgery 
(38) 
Matched 
controls 
(76) 
p - value 
Nutritional status Baseline weight (kg) 71.5 [59.0-77.8] 74.8 [61.8-83.5] 0.13 
Baseline BMI 23.0 [19.5-26.7] 24.6 [21.5-28.3] 0.46 
Weight pre-surgery 71.1 [59.5-78.0] 74.8 [61.8-83.5] 0.18 
Weight post-surgery 74.8 [59.8-79.9] 74.2 [62.8-84.7] 0.37 
Pre-operative 
medications 
Corticosteroids 4 [11%] 8[11%] 1.0 
Antibiotics 11[29%] 9[11%] 0.04 
Pre-op laboratory 
indices   
Haemoglobin (g/L) mean [SEM] 130 [2.3] 129 [1.7] 0.72 
MCV (fL) mean [SEM] 85.5 [1.0] 87.2 [0.9] 0.23 
White cell count (x10
9
/L) mean 
[SEM] 
9.3[0.5] 8.1[0.4] 0.07 
Platelet count (x10
9
/L) mean 
[SEM] 
306[14.1] 294 [9.4] 0.52 
Albumin (g/L) mean [SEM] 42.4[1.0] 41.3[0.7] 0.38 
C-reactive protein (mg/L)  8 [4-29] 14 [5-43] 0.30 
Indication for 
surgery 
Stricturing 18[47%] 40[53%] 0.11 
Penetrating 20[53%] 36[47%] 
Surgical approach Open 16 [42%] 44[58%] 0.11 
Laparoscopic 22 [58%] 32 [42%] 
Surgery type † Small bowel resection 3 [8%] 6[8%] 0.99 
Ileocaecal resection 30 [79%] 60 [79%] 
Right hemicolectomy 3[8%] 7[9%] 
Colectomy  2[5%] 3[4%] 
Stoma Primary anastomosis 37[97%] 70 [92%] 0.42 
Stoma 1[3%] 6 [8%} 
Operative course Length of surgery (hrs) 3 [2.5-3.5] 3.5 [3.0-4.0] <0.001 
Time to first bowel movement 
(days) 
3 [2-4] 3 [3-4] 0.28 
Time to eating (days) 2 [1-3] 3 [3-4] <0.001 
Length of stay (days) 6 [5-7] 6 [5-7] 0.97 
Surgical 
complications 
Anastomotic leak, abscess or 
collection 
1 [3%] 15 [20%] 0.02 
Wound dehiscence 2 [5%] 6 [8%] 0.72 
High stoma output - 2 [3%] - 
Rectal bleeding - 1 [1%] - 
Ileus - 1 [1%] - 
Readmission  Within 28 days 1 [3%] 11[14%] 0.11 
29-72 days - 3[4%] 0.55 
Disease activity at 
1 year 
Recurrence 11 [29%] 31 [41%] 0.30 
Remission 27 [71%] 45 [59%] 
 453 
  454 
 Exclusive enteral nutrition: a safe and effective bridge to surgery in Crohn’s disease – AP&T: 08/12/2016 
 
20 
 
 
Table 2:  Peri-surgical, nutritional and laboratory indices, indication for surgery, surgical approach, 455 
type, stoma formation, operative course and complications in cases and controls. Median and 456 
interquartile range (IQR) are presented unless otherwise stated. SEM denotes standard error of the 457 
mean. Differences between parametric continuous variables and in non-parametric and/or discrete 458 
variables were sought using Student’s t-test and the Mann-Whitney U test respectively. Differences 459 
between categorical variables were sought using chi-squared analyses, where n<6 Fisher’s exact test 460 
was used. † denotes matching criteria. 461 
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 489 
Supplementary Table 1: Simultaneous multivariable linear regression of factors independently 490 
associated with fold-change in CRP. 491 
 492 
Supplementary Table 2: Simultaneous multivariable linear regression including EEN and antibiotics 493 
as an interacting variable with fold-change in CRP.   494 
 495 
 496 
 497 
Variable Parameter estimate LCI UCI p - value 
(Intercept) 1.88 1.27 2.78 0.002 
EEN 0.24 0.13 0.44 <0.0001 
Antibiotics (baseline) 0.35 0.16 0.74 0.008 
Variable Parameter estimate LCI UCI p - value 
(Intercept) 1.66 1.12 2.46 0.014 
EEN 0.35 0.18 0.69 0.003 
Antibiotics (baseline) 0.85 0.30 2.43 0.767 
EEN and antibiotics (baseline) 0.17 0.04 0.75 0.021 
